IL143733A0 - Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy - Google Patents
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsyInfo
- Publication number
- IL143733A0 IL143733A0 IL14373399A IL14373399A IL143733A0 IL 143733 A0 IL143733 A0 IL 143733A0 IL 14373399 A IL14373399 A IL 14373399A IL 14373399 A IL14373399 A IL 14373399A IL 143733 A0 IL143733 A0 IL 143733A0
- Authority
- IL
- Israel
- Prior art keywords
- gamma
- narcolepsy
- treatment
- disclosed
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11374598P | 1998-12-23 | 1998-12-23 | |
PCT/US1999/030740 WO2000038672A2 (en) | 1998-12-23 | 1999-12-22 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Publications (1)
Publication Number | Publication Date |
---|---|
IL143733A0 true IL143733A0 (en) | 2002-04-21 |
Family
ID=22351244
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14373399A IL143733A0 (en) | 1998-12-23 | 1999-12-22 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
IL143733A IL143733A (en) | 1998-12-23 | 2001-06-13 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL143733A IL143733A (en) | 1998-12-23 | 2001-06-13 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Country Status (11)
Country | Link |
---|---|
US (14) | US6472431B2 (de) |
EP (1) | EP1140061B1 (de) |
JP (2) | JP4374441B2 (de) |
AT (1) | ATE238783T1 (de) |
AU (1) | AU779354B2 (de) |
CA (1) | CA2355293C (de) |
DE (1) | DE69907508T2 (de) |
DK (1) | DK1140061T3 (de) |
ES (1) | ES2193777T3 (de) |
IL (2) | IL143733A0 (de) |
WO (1) | WO2000038672A2 (de) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1140061B1 (de) | 1998-12-23 | 2003-05-02 | Orphan Medical Inc. | Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten |
DE10315640A1 (de) * | 2003-04-04 | 2004-10-14 | Ignatov, Konstantin | Verfahren zur kontrollierten Freisetzung von Komponenten in eine Lösung |
EP1629732A1 (de) * | 2004-08-27 | 2006-03-01 | Purac Biochem BV | Zussammensetzungen zur Inaktivierung von Hefen oder Schimmelpilzen in Getränken |
MX2007002682A (es) * | 2004-09-07 | 2008-03-05 | Orphan Medical Inc | Composiciones mejoradas de gamma-hidroxibutirato ghb. |
EP1809286A4 (de) * | 2004-11-10 | 2010-09-01 | Univ Columbia | Verfahren zur behandlung von bewegungsstörungen |
US7838556B2 (en) * | 2006-02-21 | 2010-11-23 | University Of Maryland, Baltimore | Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands |
US8603518B2 (en) | 2006-05-01 | 2013-12-10 | Universiteit Gent | Hydroxybutyrate and poly-hydroxybutyrate as components of animal feed or feed additives |
BRPI0602825A2 (pt) * | 2006-06-23 | 2012-04-24 | Rhodia Br Ltda | formulação de pó efervescente auto-refrigerante para bebidas e uso de formulação em pó efervescente |
WO2009129350A2 (en) * | 2008-04-15 | 2009-10-22 | Norac, Inc. | A novel process for the preparation of sodium gamma-hydroxybutyrate |
US8771735B2 (en) * | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
FR2938431B1 (fr) * | 2008-11-14 | 2013-12-20 | Debregeas Et Associes Pharma | Nouvelle composition a base d'acide gamma-hydroxybutyrique |
US8410304B2 (en) * | 2009-04-15 | 2013-04-02 | Norac Pharma | Process for preparing gamma-hydroxybutyrate |
FR2949062B1 (fr) | 2009-08-12 | 2011-09-02 | Debregeas Et Associes Pharma | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments |
FR2949061B1 (fr) | 2009-08-12 | 2013-04-19 | Debregeas Et Associes Pharma | Microgranules flottants |
US20120076865A1 (en) | 2010-03-24 | 2012-03-29 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
PL2630957T3 (pl) * | 2010-07-29 | 2020-07-13 | Ecolab Usa Inc. | Sposób oczyszczania wody pitnej dla zwierząt z zastosowaniem interwałowych dawek środka biobójczego |
ES2774932T3 (es) | 2012-11-14 | 2020-07-23 | Cj Cheiljedang Corp | Producción de sales de 4-hidroxibutirato utilizando materias primas de base biológica |
US8591922B1 (en) | 2012-12-14 | 2013-11-26 | Jazz Pharmacuticals, Inc. | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
WO2014096984A1 (en) | 2012-12-21 | 2014-06-26 | Wockhardt Limited | Stable pharmaceutical composition of sodium oxybate |
US20150376152A1 (en) | 2013-02-13 | 2015-12-31 | Metabolix, Inc. | Process for Ultra Pure Chemical Production from Biobased Raw Starting Materials |
US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
US9801852B2 (en) * | 2013-08-30 | 2017-10-31 | Jazz Pharmaceuticals, Inc. | Devices and methods for facilitating and controlling use of a medication |
AU2015326472B2 (en) | 2014-09-29 | 2020-05-28 | Zogenix International Limited | Control system for control of distribution of medication |
US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
US9750811B2 (en) | 2015-09-15 | 2017-09-05 | Boveda, Inc. | Devices and methods for controlling headspace humidity and oxygen levels |
ES2930848T3 (es) | 2015-09-23 | 2022-12-22 | Xwpharma Ltd | Profármacos de ácido gamma-hidroxibutírico, composiciones y usos de los mismos |
EP3393470B1 (de) | 2015-12-22 | 2021-01-20 | Zogenix International Limited | Metabolitresistente fenfluraminanaloga und verfahren zur verwendung davon |
ES2861774T3 (es) | 2015-12-22 | 2021-10-06 | Zogenix International Ltd | Composiciones de fenfluramina y procedimientos para prepararlas |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
EP3518975A1 (de) | 2016-08-24 | 2019-08-07 | Zogenix International Limited | Formulierung zur hemmung der bildung von 5-ht-2b-agonisten und verfahren zur verwendung davon |
EP4364794A3 (de) | 2016-09-06 | 2024-07-24 | Axsome Malta Ltd. | Solvatform von (r)-2-amino-3-phenylpropylcarbamat |
US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
MY202185A (en) | 2016-10-06 | 2024-04-15 | Jazz Pharmaceuticals Ireland Ltd | Carbamoyl phenylalaninol compounds and uses therof |
BR112019007417A2 (pt) | 2016-10-12 | 2019-07-02 | Boveda Inc | conjunto de recipiente e fechamento com umidade predeterminada e método relacionado |
US12098015B2 (en) | 2016-10-12 | 2024-09-24 | Boveda Inc. | Device for controlling headspace humidity and methods for making the same |
US20180263936A1 (en) * | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
US20180303821A1 (en) * | 2017-04-24 | 2018-10-25 | BraneQuest, Inc. | Membrane active molecules |
AU2018278332B2 (en) | 2017-06-02 | 2022-05-19 | Jazz Pharmaceuticals Ireland Limited | Methods and compositions for treating excessive sleepiness |
US11413264B2 (en) | 2017-07-31 | 2022-08-16 | Jazz Pharmaceuticals Ireland Limited | Carbamoyl phenylalaninol analogs and uses thereof |
US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
WO2019126218A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release |
US11666546B2 (en) | 2017-12-18 | 2023-06-06 | Tris Pharma, Inc | GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
WO2019126214A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release |
CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
AU2019383389A1 (en) | 2018-11-19 | 2021-05-06 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
GB201821066D0 (en) * | 2018-12-21 | 2019-02-06 | Univ Oxford Innovation Ltd | Sleep modulation |
CA3127871A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US20210186907A1 (en) * | 2019-12-24 | 2021-06-24 | Jazz Pharmaceuticals Ireland Limited | Ghb dosing |
WO2021093205A1 (en) | 2020-02-13 | 2021-05-20 | Zte Corporation | Transmission of preamble and payload messages in random access procedures |
TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
WO2022020621A1 (en) | 2020-07-24 | 2022-01-27 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
JP2023544420A (ja) | 2020-10-05 | 2023-10-23 | エックスダブリューファーマ リミテッド | ガンマ-ヒドロキシ酪酸誘導体の調節放出組成物 |
WO2022076824A1 (en) | 2020-10-08 | 2022-04-14 | Jazz Pharmaceuticals Ireland Limited | Sodium oxybate to treat idiopathic hypersomnia |
AU2021362222A1 (en) | 2020-10-16 | 2023-06-01 | Jazz Pharmaceuticals Ireland Limited | Treatment methods using ghb |
JP2024511991A (ja) | 2021-03-19 | 2024-03-18 | エックスダブリューファーマ リミテッド | ガンマ-ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態 |
EP4415701A1 (de) | 2021-10-11 | 2024-08-21 | Jazz Pharmaceuticals Ireland Limited | Verfahren zur verabreichung von oxybat |
US20230118007A1 (en) * | 2021-10-18 | 2023-04-20 | Synovent Laboratories, LLC | Medical devices and systems for use |
WO2023135150A1 (en) | 2022-01-11 | 2023-07-20 | Jazz Pharmaceuticals Ireland Limited | Method of administering oxybate |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
WO2023178288A1 (en) | 2022-03-17 | 2023-09-21 | Azora Therapeutics, Inc. | Companion diagnostics and strategies for treatment with an aryl hydrocarbon receptor agonist compound |
WO2024163966A1 (en) | 2023-02-03 | 2024-08-08 | Tris Pharma, Inc. | Low sodium oxybate once nightly composition |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB922029A (en) * | 1960-05-19 | 1963-03-27 | Equilibre Biolog L | Therapeutic composition |
US3051619A (en) | 1960-05-19 | 1962-08-28 | Equilibre Biolog L | 4-hydroxy butyric acid therapeutic compositions and process of use for clinical sedation, hypnosis, or anaesthesia |
US4183916A (en) | 1978-03-31 | 1980-01-15 | Beecham Inc. | Oral compositions |
US4374441A (en) * | 1980-05-23 | 1983-02-22 | Book Covers, Inc. | Method of making a book cover and pocket element therefor |
ZA814854B (en) | 1980-07-17 | 1982-07-28 | J Klosa | Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts |
EP0044801B1 (de) | 1980-07-17 | 1984-02-15 | Josef Dr. Klosa | Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel |
EP0235408B1 (de) | 1984-08-06 | 1991-01-09 | The University Of Toronto Innovations Foundation | Pharmazeutische Zusammensetzung und Behandlung |
US4738985A (en) | 1986-03-19 | 1988-04-19 | The University Of Toronto Innovations Foundations | Pharmaceutical composition and treatment |
US5210083A (en) | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
IT1217783B (it) * | 1988-06-03 | 1990-03-30 | Farmaceutico Ct S R L Lab | Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative |
NZ232763A (en) | 1989-03-06 | 1991-09-25 | Lilly Co Eli | Parenteral formulation comprising daptomycin with a buffer to maintain ph between 6.0 and 8.0 |
JP2564690B2 (ja) | 1990-06-14 | 1996-12-18 | 三省製薬 株式会社 | メラニン生成抑制外用剤 |
DE4113984C2 (de) | 1991-04-29 | 2002-05-08 | Koehler Chemie Dr Franz | Salze der 4-Hydroxy-Buttersäure |
US5286497A (en) | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
IT1248588B (it) | 1991-06-28 | 1995-01-19 | Gaetano Crepaldi | Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari. |
US5371424A (en) | 1992-11-25 | 1994-12-06 | Motorola, Inc. | Transmitter/receiver circuit and method therefor |
IT1271403B (it) * | 1993-03-26 | 1997-05-28 | Ct Lab Farm Srl | Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi |
IT1266565B1 (it) * | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
US5840331A (en) | 1995-06-07 | 1998-11-24 | Arch Development Corporation | Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin |
US6077545A (en) | 1995-10-30 | 2000-06-20 | Matrix Pharmaceuticals, Inc. | Process and composition for therapeutic cisplatin (CDDP) |
DE19602664A1 (de) | 1996-01-25 | 1997-08-07 | Waltenberger Karl Hans | Mittel zum Inhibieren des Algenwachstums |
CN1215338A (zh) | 1996-04-05 | 1999-04-28 | 武田药品工业株式会社 | 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物 |
IT1283782B1 (it) * | 1996-08-09 | 1998-04-30 | Ct Lab Farm Srl | Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo |
PL331536A1 (en) | 1996-08-15 | 1999-07-19 | Schering Corp | Muscarinic antagonists with an etheric bond |
US20080292700A1 (en) | 1997-04-21 | 2008-11-27 | Biovail Laboratories | Controlled release formulations using intelligent polymers |
US5990162A (en) * | 1997-08-29 | 1999-11-23 | Orphan Medical, Inc. | Method for treatment of fibromyalgia and chronic fatigue syndrome |
EP1140061B1 (de) | 1998-12-23 | 2003-05-02 | Orphan Medical Inc. | Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten |
-
1999
- 1999-12-22 EP EP99964320A patent/EP1140061B1/de not_active Expired - Lifetime
- 1999-12-22 DE DE69907508T patent/DE69907508T2/de not_active Expired - Lifetime
- 1999-12-22 WO PCT/US1999/030740 patent/WO2000038672A2/en active IP Right Grant
- 1999-12-22 CA CA002355293A patent/CA2355293C/en not_active Expired - Lifetime
- 1999-12-22 JP JP2000590626A patent/JP4374441B2/ja not_active Expired - Lifetime
- 1999-12-22 DK DK99964320T patent/DK1140061T3/da active
- 1999-12-22 IL IL14373399A patent/IL143733A0/xx active IP Right Grant
- 1999-12-22 ES ES99964320T patent/ES2193777T3/es not_active Expired - Lifetime
- 1999-12-22 AU AU20590/00A patent/AU779354B2/en not_active Expired
- 1999-12-22 AT AT99964320T patent/ATE238783T1/de active
- 1999-12-22 US US09/470,570 patent/US6472431B2/en not_active Expired - Lifetime
-
2001
- 2001-06-13 IL IL143733A patent/IL143733A/en not_active IP Right Cessation
-
2002
- 2002-07-11 US US10/194,021 patent/US6780889B2/en not_active Expired - Lifetime
-
2004
- 2004-05-07 US US10/841,709 patent/US7262219B2/en not_active Expired - Lifetime
-
2007
- 2007-07-13 US US11/777,877 patent/US7851506B2/en not_active Expired - Fee Related
-
2009
- 2009-02-10 JP JP2009028694A patent/JP5204685B2/ja not_active Expired - Lifetime
-
2010
- 2010-10-27 US US12/913,644 patent/US20110039929A1/en not_active Abandoned
-
2011
- 2011-07-13 US US13/182,324 patent/US8461203B2/en not_active Expired - Fee Related
-
2012
- 2012-04-13 US US13/446,940 patent/US8263650B2/en not_active Expired - Fee Related
- 2012-04-13 US US13/446,892 patent/US8324275B2/en not_active Expired - Fee Related
- 2012-11-26 US US13/685,561 patent/US8859619B2/en not_active Expired - Fee Related
-
2013
- 2013-03-06 US US13/787,437 patent/US8952062B2/en not_active Expired - Fee Related
-
2014
- 2014-04-10 US US14/250,116 patent/US20150073052A1/en not_active Abandoned
-
2015
- 2015-11-09 US US14/936,496 patent/US9539330B2/en not_active Expired - Fee Related
-
2016
- 2016-11-18 US US15/355,599 patent/US20170224825A1/en not_active Abandoned
-
2019
- 2019-04-12 US US16/382,533 patent/US20190328882A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL143733A0 (en) | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | |
DE69528039D1 (de) | Inhibitoren der fettsäuresynthese als antimikrobielle mittel | |
WO2000047255A8 (en) | Method and apparatus for automatically controlling the level of medication | |
MXPA02007639A (es) | Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva. | |
BE2012C040I2 (de) | ||
PT867184E (pt) | Utilizacao de tiagabina para o tratamento de desordens do sono | |
WO2001056567A8 (en) | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors | |
WO2001043732A3 (en) | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies | |
MXPA03000188A (es) | Metodo de tratamiento de enfermedades relacionadas con neutroficos con anestesicos locales. | |
EP1952809A3 (de) | Formulierungen für die Reduzierung der Brustdichte mit 4-Hydroxi-Tamoxifen | |
HK1047707A1 (zh) | (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途 | |
WO1999015643A3 (en) | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE | |
AU3258801A (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
WO1998026770A3 (en) | The topical use of kappa opioid agonists to treat ocular pain | |
NZ506681A (en) | Disinfecting composition | |
WO2002005642A3 (en) | Synergistic biocidal compositions | |
DE60013823D1 (de) | Teilbare hüllenanordnung mit okklusionsballon | |
WO2002036108A3 (en) | Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases | |
WO2000059940A3 (en) | Platelet-derived growth factor related gene and protein | |
AU6846300A (en) | Use of cyamemazine for cold turkey benzodiazepine treatment | |
WO2002067851A3 (en) | Method for treating fibrotic diseases or other indications iiic | |
AU2976095A (en) | Use of selegilin in the treatment of epileptic conditions | |
AU4530796A (en) | Treating disorders characterised by excessive cell proliferation with sclareolide | |
AUPP379698A0 (en) | Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions | |
BR0016720A (pt) | Uso de trimebutina para tratamento de dores |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |